148 related articles for article (PubMed ID: 29048134)
41. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
[TBL] [Abstract][Full Text] [Related]
42. Treatment of necrobiotic xanthogranuloma with 2-chlorodeoxyadenosine.
Sutton L; Sutton S; Sutton M
Skinmed; 2013; 11(2):121-3. PubMed ID: 23745232
[TBL] [Abstract][Full Text] [Related]
43. Lenalidomide as first-line therapy for elderly CLL patients.
Gilbert JA
Lancet Oncol; 2013 Aug; 14(9):e345. PubMed ID: 24058966
[No Abstract] [Full Text] [Related]
44. [Treatment of MDS].
Usuki K
Rinsho Ketsueki; 2014 Oct; 55(10):1882-92. PubMed ID: 25297752
[No Abstract] [Full Text] [Related]
45. Treatment of prurigo nodularis with lenalidomide.
Ossorio-García L; Jiménez-Gallo D; Rodríguez-Mateos ME; Arjona-Aguilera C; Linares-Barrios M
Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27891738
[TBL] [Abstract][Full Text] [Related]
46. Necrobiotic xanthogranuloma with multiple myeloma.
Bhari N; Chiramel MJ; Vedi KK; Nath D; Sandip S; Kumar R; Kumar L; Sharma VK; Sethuraman G
Clin Exp Dermatol; 2015 Oct; 40(7):811-4. PubMed ID: 25809408
[No Abstract] [Full Text] [Related]
47. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Scott GB; Carter C; Parrish C; Wood PM; Cook G
Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
[TBL] [Abstract][Full Text] [Related]
48. [Necrobiotic xanthogranuloma. Differential diagnosis, treatment and systemic involvement. Case report].
Sanz-Marco E; España E; López-Prats MJ; Chirivella-Casanova M; Aviño J; Díaz-Llopis M
Arch Soc Esp Oftalmol; 2014 May; 89(5):186-9. PubMed ID: 24269389
[TBL] [Abstract][Full Text] [Related]
49. Intravenous immunoglobulin for treatment of necrobiotic xanthogranuloma.
Goyal A; O'Leary D; Vercellotti G; Miller D; McGlave P
Dermatol Ther; 2019 Jan; 32(1):e12744. PubMed ID: 30221815
[No Abstract] [Full Text] [Related]
50. Necrobiotic xanthogranuloma with giant cell hepatitis, successfully treated with intravenous immunoglobulins.
Pedrosa AF; Ferreira O; Calistru A; Mota A; Baudrier T; Sarmento JA; Bettencourt H; Azevedo F
Dermatol Ther; 2015; 28(2):68-70. PubMed ID: 25650024
[No Abstract] [Full Text] [Related]
51. Slowly growing yellow nodules: challenge. Necrobiotic xanthogranuloma.
Gergen N; Biebl K; Berg BC; Suwattee P
Am J Dermatopathol; 2011 Feb; 33(1):92-3, 103-4. PubMed ID: 20644464
[No Abstract] [Full Text] [Related]
52. Successful multimodality treatment of recalcitrant necrobiotic xanthogranuloma using electron beam radiation and intravenous immunoglobulin.
Nambudiri VE; McLaughlin C; Lo TC; Zembowicz A; Moschella S
Clin Exp Dermatol; 2016 Mar; 41(2):179-82. PubMed ID: 26206141
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranuloma Associated With Multiple Myeloma.
Henning C; Meyers S; Swift R; Eades B; Bussell L; Spektor TM; Berenson JR
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e492-e495. PubMed ID: 32389673
[No Abstract] [Full Text] [Related]
54. Distinctive Pattern of Adipophilin Expression in Necrobiotic Xanthogranuloma.
Saggini A; Cota C; Cerroni L
Am J Dermatopathol; 2016 Jun; 38(6):468-70. PubMed ID: 26981735
[No Abstract] [Full Text] [Related]
55. Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome.
Naghashpour M; Setoodeh R; Moscinski L; Bergier G; McCardle T; Glass F; Sokol L
Am J Dermatopathol; 2011 Dec; 33(8):855-7. PubMed ID: 22042261
[TBL] [Abstract][Full Text] [Related]
56. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Anderson KC; Prince HM
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
[No Abstract] [Full Text] [Related]
57. The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide.
Devoe CE; Li JY; Demopoulos AM
J Neurooncol; 2014 Aug; 119(1):217-20. PubMed ID: 24847966
[No Abstract] [Full Text] [Related]
58. Treatment of refractory prurigo nodularis with lenalidomide.
Kanavy H; Bahner J; Korman NJ
Arch Dermatol; 2012 Jul; 148(7):794-6. PubMed ID: 22801610
[No Abstract] [Full Text] [Related]
59. Necrobiotic xanthogranuloma without a monoclonal gammopathy.
Seastrom S; Bookout A; Hogan DJ
Cutis; 2014 Dec; 94(6):293-6. PubMed ID: 25566570
[TBL] [Abstract][Full Text] [Related]
60. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.
Negoro E; Radivoyevitch T; Polprasert C; Adema V; Hosono N; Makishima H; Przychodzen B; Hirsch C; Clemente MJ; Nazha A; Santini V; McGraw KL; List AF; Sole F; Sekeres MA; Maciejewski JP
Leukemia; 2016 Dec; 30(12):2405-2409. PubMed ID: 27560106
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
